GlassScriptPhysician profile
Phong C Hu
NPI 1104017169
$4,180.12
in general payments reported to CMS, 2019-2025
34 companies · $1,072 in 2025
The $1,072 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $807 · 2020: $153 · 2022: $457 · 2023: $877 · 2024: $815 · 2025: $1,072.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,764.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,763.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $646.87 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $613.58 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $391.53 | 2019-2024 | Xarelto |
| Boston Scientific Corporation | $292.58 | 2019-2024 | Lux-Dx Insertable Cardiac Monitor, Watchman Flx |
| Merck Sharp & Dohme LLC | $271.65 | 2022-2025 | Verquvo |
| Amgen INC. | $215.83 | 2019-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $175.74 | 2019-2025 | Camzyos, Eliquis |
| Edwards Lifesciences Corporation | $172.60 | 2025 | Sapien 3 Ultra Resilia |
| Kiniksa Pharmaceuticals, LTD. | $146.42 | 2022-2023 | Arcalyst |
| Boehringer Ingelheim Pharmaceuticals, INC. | $142.26 | 2023-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $126.57 | 2019-2025 | Andexxa, Lokelma, Farxiga |
| Penumbra, INC. | $125.09 | 2023 | Indigo System |
| Regeneron Healthcare Solutions, INC. | $72.44 | 2019-2025 | Evkeeza |
| Abbott Laboratories | $71.65 | 2019-2023 | Amplatzer Amulet, Mitraclip |
| Baxter Healthcare | $65.81 | 2024-2025 | Hillrom - Cardiac Ambulatory Monitor |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $62.37 | 2023-2025 | Barostim Neo System |
| Kiniksa Pharmaceuticals International, Plc | $56.19 | 2024 | Arcalyst |
| Inspire Medical Systems, INC. | $54.35 | 2024 | Inspire |
| Philips North America LLC | $51.47 | 2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $50.56 | 2019-2025 | Lifevest |
| Lantheus Medical Imaging, INC. | $42.97 | 2019-2025 | |
| Esperion Therapeutics, INC. | $42.21 | 2022-2023 | Nexletol |
| Alnylam Pharmaceuticals INC. | $36.94 | 2024-2025 | Amvuttra |
| Sanofi-Aventis U.S. LLC | $36.78 | 2019 | |
| Kestra Medical Technology Services, INC. | $30.99 | 2024 | Assure Wcd |
| Genzyme Corporation | $24.71 | 2025 | |
| Medtronic, INC. | $24.41 | 2022 | |
| Gilead Sciences, INC. | $23.60 | 2019 | |
| Arbor Pharmaceuticals, INC. | $21.68 | 2019 | |
| Amarin Pharma, INC. | $20.25 | 2020 | |
| Scpharmaceuticals INC. | $19.42 | 2025 | |
| Irhythm Technologies, INC. | $18.12 | 2024 | Zio Monitor, Zio Xt Patch |
| Novo Nordisk INC | $17.48 | 2022 | |
| Bardy Diagnostics, INC. | $15.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phong Hu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.